natgillin/translations-raw huggingface dataset:
These rates were significantly greater (p &lt; 0.0001) against a random effects meta-analysis of localisation rates from published literature for colloidal lymphatic mapping agents as used in European clinical practice.
Ti deleži so bili pomembno večji (p &lt; 0,0001) v primerjavi z metaanalizo deležev lokalizacije z naključnimi učinki iz objavljene literature za koloide za mapiranje bezgavk, kot se uporabljajo v evropski klinični praksi.
These reactions were more common in patients with baseline eGFR ≥ 30 and &lt; 60 mL/min/1.73m2 (18.5% dapagliflozin 10 mg vs 9.3% placebo).
Te reakcije so bile pogostejše pri bolnikih z izhodiščno ocenjeno hitrostjo glomerularne filtracije [eGFR] ≥ 30 in &lt; 60 ml/min/1,73 m2 (18,5 % z 10 mg dapagliflozina in 9,3 % s placebom).
These results were similar to the immune response rates induced by concomitant administration of a single dose of Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. at separate injection sites.
Ti rezultati so bili podobni deležem imunskega odziva pri sočasnem cepljenju z enkratnim odmerkom cepiva z živim virusom noric (Oka/Merck) ter cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck &amp; Co., Inc., na različnih vbodnih mestih.
These studies indicate that excessive aliskiren exposure ( &gt; 400-fold higher in 8-day old rats compared with adult rats) and high acute toxicity in juvenile rats are caused by immature MDR1, which suggests that in paediatric patients with immature MDR1, there is a potential for aliskiren overexposure (see sections 4.2, 4.3 and 5.2).
Rezultati teh študij kažejo, da močno povečano izpostavljenost aliskirenu (ki je pri 8 dni starih podganah &gt; 400-krat višja kot pri odraslih) in veliko akutno toksičnost pri podganjih mladičih povzroča nezrelost prenašalcev MDR1, kar lahko pomeni, da pri pediatričnih bolnikih z nezrelimi prenašalci MDR1 lahko pride do prevelike izpostavljenosti aliskirenu (glejte poglavja 4.2, 4.3 in 5.2).
These substitutions conferred low level resistance (EC50 &lt; 1 nM) for genotype 1b, and higher levels of resistance for genotype 1a (EC50 up to 350 nM).
Te substitucije so bile pri genotipu 1b povezane z odpornostjo nizke stopnje (EC50 &lt; 1 nM), pri genotipu 1a pa z odpornostjo višje stopnje (EC50 do 350 nM).
These were classified as common (≥1/100 to &lt; 1/10) or uncommon (≥1/1,000 to &lt; 1/100).
Te so razvrstili kot pogoste (≥1/100 do &lt; 1/10) in občasne (≥1/1.000 do &lt; 1/100).
They are classified according to the following convention: very common (≥1/10), common≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from the available data).
Razvrščeni so v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1000), zelo redki ( &lt; 1/10.000) ali pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov).
They are classified according to the subsequent convention: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) or not known (cannot be estimated from the available data).
Razvrščeni so v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1000), zelo redki ( &lt; 1/10.000) ali pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov).
They are present in plasma at levels that are &lt; 10% of erlotinib and display similar pharmacokinetics as erlotinib.
V plazmi sta prisotna v koncentracijah, manjših od 10 % koncentracije erlotiniba, in kažeta podobno farmakokinetiko kakor erlotinib.
They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from the available data).
Razvrščeni so po organskih sistemih in po pogostnosti v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000) ali neznana pogostnost (ni je mogoče oceniti iz razpoložljivih podatkov).
They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from the available data).
Razvrščeni so po organskih sistemih v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1000), zelo redki ( &lt; 1/10.000) ali pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov).
They are ranked according to system organ class and classified according to the following convention: very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from the available data).
Razvrščene so po organskih sistemih po naslednjem dogovoru: zelo pogosti (1/10); pogosti (1/100 do &lt; 1/10); občasni (1/1.000 do &lt; 1/100); redki (1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
They are ranked under headings of SOC and frequency using the following convention: very common ( 1/10), common (1 /100 to &lt; 1 /10), uncommon ( 1/1,000 to &lt; 1 /100), rare (1 /10,000 to &lt; 1 /1,000), very rare ( &lt; 1 /10,000), not known (cannot be estimated from the available data).
Razvrščeni so po organskih sistemih in pogostnosti: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
They were reported in 54% of the patients in the 70 to ≤100 kg weight group, 70% of the patients in the &gt; 100 to ≤120 kg weight group, and 75% of patients in the &gt; 120 kg weight group, respectively.
O njih so poročali pri 54 % bolnikov s telesno maso od 70 do ≤ 100 kg, 70 % bolnikov s telesno maso od &gt; 100 do ≤ 120 kg in 75 % bolnikov s telesno maso &gt; 120 kg.
Thiomersal &lt; 120 μg.
Tiomersal &lt; 120 μg.
Third monthly weighing where bodyweight loss &lt; 3% per month since previous weighing
Tretje mesečno tehtanje, kjer je izguba telesne mase &lt; 3 % na mesec v primerjavi s prejšnjim mesečnim tehtanjem
Thirteen of these ONJ cases occurred in postmenopausal women with osteoporosis during the phase III clinical trial extension following treatment with Prolia for up to 10 years (0.3%; &lt; 0.1 events per 100 subject-years).
Trinajst od teh primerov osteonekroze čeljustnice se je pojavilo pri ženskah po menopavzi z osteoporozo med podaljšanjem kliničnega preskušanja III. faze po zdravljenju z zdravilom Prolia do 10 let (0,3 %; &lt; 0,1 dogodek na 100 preiskovancev-let).
Thirteen percent (6/45) of the tenofovir disoproxil fumarate group, 13% (6/45) of the emtricitabine plus tenofovir disoproxil fumarate group, and 9% (2/22) of the entecavir group had a confirmed increase in serum creatinine ≥ 0.5 mg/dl or confirmed serum phosphate of &lt; 2 mg/dl.
Trinajst odstotkov (6/45) v skupini z dizoproksiltenofovirijevim fumaratom, 13% (6/45) v skupini z emtricitabinom in dizoproksiltenofovirijevim fumaratom in 9% (2/22) v skupini z entekavirjem je imelo potrjeno zvišanje serumske koncentracije kreatinina za ≥ 0,5 mg/dl ali potrjeno serumsko koncentracijo fosfata &lt; 2 mg/dl.
Thirty two percent (30/94) of subjects demonstrated &gt; 15 percentile decrease in height-for-age percentile 5 years after completion of therapy (see sections 4.8 and 5.1).
Dvaintrideset odstotkov (30/94) preiskovancev je imelo 5 let po koncu zdravljenja zmanjšanje percentila telesne višine za starost &gt; 15 percentilov (glejte poglavji 4.8 in 5.1).
Thirty two percent (30/94) of subjects demonstrated &gt; 15 percentile decrease in height-for-age percentile 5 years after completion of therapy (see sections 4.8 and 5.1).
Pri dvaintridesetih odstotkih (30/94) preiskovancev je bilo 5 let po koncu zdravljenja zmanjšanje percentila telesne višine za starost &gt; 15 percentilov (glejte poglavji 4.8 in 5.1).
Thirty-six (36) months of Glivec treatment significantly prolonged RFS compared to 12 months of Glivec treatment (with overall Hazard Ratio (HR) = 0.46 [0.32, 0.65], p &lt; 0.0001) (Table 8, Figure 1).
Šestintrideset (36) mesecev zdravljenja z zdravilom Glivec je statistično značilno bolj podaljšalo preživetje brez ponovitve bolezni v primerjavi z 12 meseci zdravljenja z zdravilom Glivec (z razmerjem tveganj 0,46 [0,32, 0,65], p &lt; 0,0001) (preglednica 8, slika 1).
This 15% difference between treatment groups was confirmed at 24 months (53% Visudyne versus 38% placebo, p &lt; 0.001).
Ta 15 % razlika med obravnavanima skupinama je bila potrjena po 24 mesecih (53 % za zdravilo Visudyne proti 38 % za placebo, p &lt; 0,001).
This 18 month difference was statistically significant with a hazard ratio of reduction of risk of death in the MPT arm of 0.59, 97.5% confidence interval of 0.42-0.84 and p-value of &lt; 0.001 (see Figure 1).
Ta 18-mesečna razlika je bila statistično pomembna z znižanjem razmerja nevarnosti tveganja za smrti v skupini MPT z 0,59; 97,5 %, interval zaupanja 0,42-0,84 in vrednostjo p &lt; 0,001 (glejte sliko 1).
This clearance was achieved in 69% (20/29) of the Fabrazyme treated patients, but in none of the placebo patients (p &lt; 0.001).
Očistek je bil dosežen pri 69 % (20/29) bolnikov, zdravljenih z zdravilom Fabrazyme, in pri nobenem od tistih, ki so prejemali placebo (p &lt; 0,001).
This difference was statistically significant (p &lt; 0.001) for the pre-specified analysis at day 14 and day 28.
Ta razlika je bila za vnaprej določeno analizo 14. dne in 28. dne statistično signifikantna (p &lt; 0,001).
This difference was statistically significant (p &lt; 0.001).
Ta razlika je bila statistično signifikantna (p &lt; 0,001).
This enhancement in efficacy included loss of serum HCV ( &lt; 100 copies/ml by PCR), improvement in hepatic inflammation, and normalisation of ALT, and was sustained when measured 6 months after the end of treatment.
Ta okrepitev učinkovitosti je vključevala odsotnost HCV v serumu ( &lt; 100 kopij/ml pri PCR), izboljšanje vnetja jeter in normalizacijo ALT in je bila še ohranjena ob merjenju 6 mesecev po koncu terapije.
This finding was further supported by a statistically significant decrease in GL-3 inclusions in kidney, heart and skin combined and in the individual organs in patients treated with agalsidase beta compared to placebo patients (p &lt; 0.001).
Ta izsledek je bil podprt tudi s statistično občutnim zmanjšanjem skupnega števila inkluzij GL-3 v ledvicah, srcu in koži ter v posameznih organih bolnikov, zdravljenih z agalzidazo beta, v primerjavi s tistimi, ki so prejemali placebo (p &lt; 0,001).
This increased risk for toxicity based on CD4 count thresholds has not been detected in patients with undetectable (i.e. &lt; 50 copies/ml) plasma viral load.
Pri bolnikih z nedoločljivim virusnim bremenom v plazmi (tj. &lt; 50 kopij/ml) ni bilo povečano tveganje toksičnosti, ki je povezano z mejnim številom celic CD4.
This interim analysis showed a TTP risk reduction of 45 % (95 % CI; 29-57 %, p &lt; 0.0001) for patients treated with combination therapy of bortezomib and pegylated liposomal doxorubicin.
Vmesna analiza je pokazala zmanjšanje tveganja za TTP za 45% (95% IZ; od 29 do 57%, p &lt; 0,0001) pri bolnikih, ki so prejemali kombinirano terapijo z bortezomibom in pegiliranim liposomskim doksorubicinom.
This interim analysis showed a TTP risk reduction of 45% (95% CI: 29-57%), p &lt; 0.0001. The median TTP was
Vmesna analiza je pokazala zmanjšanje tveganja za TTP za 45% (95% IZ; od 29 do 57%), p &lt; 0,0001.
This interim analysis showed a TTP risk reduction of 45% (95% CI; 29-57%, p &lt; 0.0001) for patients treated with combination therapy of bortezomib and pegylated liposomal doxorubicin.
Vmesna analiza je pokazala zmanjšanje tveganja za TTP za 45 % (95 % CI; od 29 do 57 %, p &lt; 0,0001) pri bolnikih, ki so prejemali kombinirano terapijo z bortezomibom in pegiliranim liposomskim doksorubicinom.
This interim analysis showed a TTP risk reduction of 45% (95% CI; 29-57%, p &lt; 0.0001) for patients treated with combination therapy of bortezomib and pegylated liposomal doxorubicin.
Vmesna analiza je pokazala zmanjšanje tveganja za TTP za 45% (95% IZ; od 29 do 57%, p &lt; 0,0001) pri bolnikih, ki so prejemali kombinirano terapijo z bortezomibom in pegiliranim liposomskim doksorubicinom.
This interim analysis showed a TTP risk reduction of 45% (95% CI; 29-57%, p &lt; 0.0001) for patients treated with combination therapy of VELCADE and pegylated liposomal doxorubicin.
Vmesna analiza je pokazala zmanjšanje tveganja za TTP za 45% (95% IZ; od 29 do 57%, p &lt; 0,0001) pri bolnikih, ki so prejemali kombinirano terapijo z zdravilom VELCADE in pegiliranim liposomskim doksorubicinom.
This is a serious reaction which may occur uncommonly (≥ 1/1,000 to &lt; 1/100) (see section 4.4).
To je resna reakcija, ki se lahko pojavi občasno (≥ 1/1.000 do &lt; 1/100) (glejte poglavje 4.4).
This leaflet was last last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt;
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL} &gt;
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne &lt; datum &gt;
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL}
This leaflet was last revised in &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano v &lt; { mesecu leta LLLL} &gt; .
This leaflet was last revised in &lt; date of Commission Decision &gt;
Navodilo je bilo nazadnje revidirano dne &lt; datum odločbe Komisije &gt;
This leaflet was last revised in &lt; MM/YYYY &gt;
Navodilo je bilo nazadnje revidirano dne &lt; MM/LLLL &gt;
This leaflet was last revised in &lt; MM/YYYY &gt;
Navodilo je bilo nazadnje revidirano dne.
This leaflet was last revised in &lt; MM/YYYY &gt; &lt; month YYYY &gt; .
Navodilo je bilo nazadnje revidirano dne {MM/YYYY}
This leaflet was last revised in &lt; MM/YYYY &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt;
This leaflet was last revised in &lt; Month YYYY &gt;
Navodilo je bilo nazadnje revidirano
This leaflet was last revised in &lt; month YYYY &gt;
To navodilo je bilo nazadnje revidirano dne &lt; mesec LLLL &gt;
This leaflet was last revised in &lt; Month YYYY &gt; .
Navodilo je bilo nazadnje revidirano
This leaflet was last revised in &lt; Month YYYY &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; mesec LLLL &gt;
This leaflet was last revised in &lt; {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL}
This leaflet was last revised in &lt; {MM/YYYY} &gt;
Navodilo je bilo nazadnje revidirano
This leaflet was last revised in &lt; {MM/YYYY} &gt;
Navodilo je bilo nazadnje revidirano &lt; {MM/LLLL} &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt;
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt;
Navodilo je bilo nazadnje revidirano dne { MM/LLLL }
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY}
Navodilo je bilo nazadnje revidirano &lt; {MM/LLLL} &gt; &lt; {mesec LLLL}
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY}. &gt;
Navodilo je bilo nazadnje revidirano &lt; {MM/LLLL} &gt; &lt; {mesec LLLL}. &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY}. &gt;
Navodilo je bilo nazadnje revidirano dne
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY}. &gt;
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL}. &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY}. &gt;
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL} &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY}. &gt;
Navodilo je bilo odobreno {MM/LLLL}
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt;
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL} &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL}. &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL} &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec YYYY} &gt; .
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano {MM/LLLL}
This leaflet was last revised in &lt; {MM/YYYY} &gt; Other sources of information
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; Drugi viri informacij
This leaflet was last revised in &lt; {MM/YYYY} &gt; .
Navodilo je bilo nazadnje revidirano &lt; {MM/LLLL} &gt; .
This leaflet was last revised in &lt; {MM/YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt;
This leaflet was last revised in &lt; {MM/YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; .
This leaflet was last revised in &lt; {MM/YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
This leaflet was last revised in &lt; {MM/YYYY} &gt; : Other sources of information
Navodilo je bilo nazadnje revidirano dne {MM/LLLL} Drugi viri informacij
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirane dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL} &gt; .
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; &lt; {mesec LLLL} &gt; .
This leaflet was last revised in &lt; {MM/YYYY} &gt; &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
This leaflet was last revised in &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano &lt; {mesec LLLL} &gt; .
This leaflet was last revised in &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne &lt; {mesec LLLL} &gt; .
This leaflet was last revised in &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne {mesec LLLL}.
This leaflet was last revised in &lt; {month YYYY} &gt; .
Navodilo je bilo nazadnje revidirano dne {mesec/LLLL}.
This leaflet was last revised in JUNE/2016 Other sources of information
Navodilo je bilo nazadnje revidirano dne &lt; {MM/LLLL} &gt; Drugi viri informacij
This leaflet was last revised in MM/YYYY.
Navodilo je bilo nazadnje revidirano dne &lt; mesec//LLLL &gt;
This leaflet was last revised in: &lt; Month YYYY &gt;
Navodilo je bilo nazadnje revidirano dne &lt; mesec/LLLL &gt;
This may result in lowered pharmacodynamic responses in heavy patients ( &gt; 95 kg).
To lahko povzroči manjše farmakodinamične odzive pri debelih bolnikih ( &gt; 95 kg).
This medicinal product has not been studied in severe renal impairment (CrCl &lt; 30 ml/min or eGFR &lt; 30 ml/min/1.73 m2) or end-stage renal disease (ESRD).
To zdravilo ni bilo raziskano pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 30 ml/min ali eGFR &lt; 30 ml/min/1,73 m2) in bolnikih s končno odpovedjo ledvic.
This medicine is subject to additional monitoring.
&lt; Za to zdravilo se izvaja dodatno spremljanje varnosti.
This medicine should not be used in children and adolescents ( &lt; 18 years) because the safety and efficacy have not yet been fully established.
Tega zdravila se ne sme uporabljati pri otrocih in mladostnikih ( &lt; 18 let), ker varnost in učinkovitost še nista bili popolnoma ugotovljeni.
This reduction in urinary CTx levels was significantly correlated with the primary efficacy endpoint SMPR (Kendall-tau-b (p &lt; 0.001)).
Znižanje koncentracij CTx v seču je bilo pomembno v korelaciji s primarnim ciljem raziskave učinkovitosti – stopnjo hitrosti obolevnosti okostja (Kendall-tau-b (p &lt; 0,001)).
This reduction in urinary CTx levels was significantly correlated with the primary efficacy endpoint SMPR (Kendall-tau-b (p &lt; 0.001)).
Znižanje koncentracij CTx v seču je bilo značilno v korelaciji s primarnim ciljem raziskave učinkovitosti SMPR (Kendall-tau-b (p &lt; 0,001)).
This regimen was administered every three weeks for 4 cycles in case at least a minor response (≥ 25 % reduction in bidimensionally measured tumour size) was observed after 2 cycles.
To terapevtsko shemo so uporabljali vsake tri tedne za 4 cikle, če so po 2 ciklih opazili vsaj manjši odziv ( &gt; 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).
This specific group had a higher risk (19%; N = 10/53) of developing elevations in ALT and/or AST &gt; 3 x ULN indicating that appropriate care should be exercised when initiating sitaxentan in this patient population.
Ta specifična skupina je imela večje tveganje (19 %, n = 10/53) za zvišanje ALT in/ali AST &gt; 3 × ZMN, kar kaže, da je v primeru uvedbe sitaksentana v tej populaciji bolnikov potrebna ustrezna skrb.
This study also included patients with classic containing CNV with a visual acuity score &gt; 70 letters (20/40).
V to študijo so bili vključeni tudi bolniki s CNV, ki je bila deloma klasična, in z oceno vidne ostrine &gt; 70 črk (20/40).
This study included patients of all three resistance categories (MDRH &amp; R-, pre-XDR- and XDR-TB).
Študija je vključevala bolnike z vsemi tremi kategorijami odpornosti (MDRH &amp; R, pre-XDR in XDR-TB).
This study involved 423 patients with chronic renal impairment (estimated glomerular filtration rate &lt; 50 ml/min).
Študija je vključevala 423 bolnikov s kronično ledvično okvaro (ocenjena hitrost glomerulne filtracije &lt; 50 ml/min).
This subject harboured &lt; 1% HCV S282T at baseline and developed S282T ( &gt; 99%) at 4 weeks post-treatment which resulted in a 13.5-fold change in sofosbuvir EC50 and reduced viral replication capacity.
Ta oseba je bila ob izhodišču nosilec &lt; 1 % HCV S282T in je razvila S282T ( &gt; 99 %) 4 tedne po zdravljenju, kar je povzročilo 13,5-kratno spremembo EC50 za sofosbuvir in zmanjšalo replikacijsko sposobnost virusa.
This translates to a reduction in the rate of moderate to severe exacerbations of 25% (95% CI: 19% to 31%; p &lt; 0.001) compared with placebo, 12% compared with salmeterol (95% CI: 5% to 19%, p=0.002) and 9% compared with FP (95% CI: 1% to 16%, p=0.024).
Preneseno to pomeni zmanjšanje števila zmernih do hudih poslabšanj za 25 % (95-odstotni IZ: 19 % do 31 %; p &lt; 0,001) v primerjavi s placebom, 12 % v primerjavi s salmeterolom (95-odstotni IZ: 5 % do 19 %, p = 0,002) in 9 % v primerjavi s FP (95-odstotni IZ: 1 % do 16 %, p = 0,024).
This was achieved in 28.7% of the patients in the group receiving daily methylnaltrexone 12 mg (p &lt; 0.001 vs. placebo), in 14.9% of those receiving it every other day (p=0.012 vs. placebo), and in 6.2% of the placebo treated patients.
Doseglo ga je 28,7% bolnikov v skupini, ki je dnevno prejemala metilnaltrekson 12 mg (p &lt; 0,001 v primerjavi s placebom), 14,9% bolnikov, ki so ga prejemali vsak drugi dan (p = 0,012 v primerjavi s placebom) in 6,2% bolnikov, ki so dobivali placebo.
This was achieved in 59% of the patients in the group receiving daily methylnaltrexone 12 mg (p &lt; 0.001 vs. placebo), in 61% of those receiving it every other day (p &lt; 0.001 vs. placebo), and in 38% of the placebo treated patients.
Doseglo ga je 59 % bolnikov v skupini, ki je dnevno prejemala metilnaltrekson 12 mg (p &lt; 0,001 v primerjavi s placebom), 61 % bolnikov, ki so ga prejemali vsak drugi dan (p &lt; 0,001 v primerjavi s placebom) in 38 % bolnikov, ki so dobivali placebo.